Save time and jump to the most important pieces.
NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors. Brown previously served for 10 years on the Board of directors of Brown-Forman Corporation, a large American wine and spirits company listed on the New York Stock Exchange. The brands in Brown-Forman's portfolio include Jack Daniel's and Woodford Reserve whiskeys, Benriach scotch, Herradura tequila and Finlandia vodka. Brown is an attorney at Adams and Reese LLP, a
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
NASHVILLE, Tenn., Oct. 31, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2024 financial results and provide a company update after the market closes on Thursday, Nov. 7, 2024. A conference call will be held on Nov. 7 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIdd190691b1df432e9f1f65383f53b384. Once registered, participants can dial in from their phone using a dial-in and PIN
NASHVILLE, Tenn., Aug. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2024. Highlights include: $9.9 million in net revenue during the second quarter of 2024, an increase of 16% sequentially from the first quarter of 2024.Adjusted earnings of $0.2 million, which represents a $0.8 million improvement over the prior period in 2024.$78.5 million in assets, $52.5 million in liabilities and $26.3 m
NASHVILLE, Tenn., July 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2024 financial results and provide a company update after the market closes on Tuesday, Aug. 6, 2024. A conference call will be held on Aug. 6 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIfa6a94515e5548c28e9d77d03c95a13e. Once registered, participants can dial in from their phone using a dial-in and PIN
NASHVILLE, Tenn., Oct. 31, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2024 financial results and provide a company update after the market closes on Thursday, Nov. 7, 2024. A conference call will be held on Nov. 7 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIdd190691b1df432e9f1f65383f53b384. Once registered, participants can dial in from their phone using a dial-in and PIN
NASHVILLE, Tenn., Aug. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2024. Highlights include: $9.9 million in net revenue during the second quarter of 2024, an increase of 16% sequentially from the first quarter of 2024.Adjusted earnings of $0.2 million, which represents a $0.8 million improvement over the prior period in 2024.$78.5 million in assets, $52.5 million in liabilities and $26.3 m
NASHVILLE, Tenn., July 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2024 financial results and provide a company update after the market closes on Tuesday, Aug. 6, 2024. A conference call will be held on Aug. 6 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIfa6a94515e5548c28e9d77d03c95a13e. Once registered, participants can dial in from their phone using a dial-in and PIN
10-Q - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
8-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
10-Q - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.05) per share. This is a 145.45 percent decrease over earnings of $0.11 per share from the same period last year. The company reported $8.50 million in sales this quarter. This is a 7.88 percent decrease over sales of $9.22 million the same period last year.
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. • Target (NYSE:TGT) is estimated to report quarterly earnings at $2.22 per share on revenue of $29.33 billion. • 2seventy bio (NASDAQ:TSVT) is expected to report quarterly loss at $0.99 per share on revenue of $14.71 million. • CLPS (NASDAQ:CLPS) is expected to report earnings for its first quarter. • Seres Therapeutics (NASDAQ:MCRB) is projected to report quarterly loss at $0.50 per share on revenue of $350 thousand. • Vivid Seats (NASDAQ:SEAT) is expected to report quarterly earnings at $0.06 per share on revenue of $183.67 million. • Nuwellis (N